Recipharm Boosts Inhalation And Injectables Manufacturing By Acquiring UK’s Consort Medical

Sweden's Recipharm has agreed to buy UK-based Consort Medical for £505m ($652m) to become a leading inhalation-device company. 

Business handshake / contract agreement flat vector icon for apps and websites - Vector

Swedish pharmaceutical group Recipharm AB announced on 18 November that it had struck a deal to buy UK-based respiratory device and contract manufacturer Consort Medical PLC for £505m ($652m), bolstering Recipharm's annual revenue to $1.1bn.

Recipharm, which develops and manufactures products for pharmaceutical and smaller R&D companies on a contract basis, said the deal would raise its scale and profitability, giving it annual sales of SEK10.8bn ($1

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

Deals Shaping The Medtech And Diagnostics Industries, March 2025

 
• By 

An interactive look at medtech and diagnostics deals made during March 2025. Data courtesy of Biomedtracker.

Roar Of Eargo-hearX Merger Echoes Through US OTC Hearing Aid Market

 

The firms recently announced they will operate as combined company LXE Hearing marketing Eargo’s namesake line and hearX’s Lexie brands. Eargo majority owner Patient Square Capital added $100m to its investment.

Anglonordic 25: Women’s Health Needs Therapeutic Success To Encourage Wider Investment

 

Health tech is at the forefront of the women's health sector, securing 38% of venture capital in 2024. However, panelists at the Anglonordic Life Science Conference held 3 April asserted that a successful therapeutic breakthrough is key to gaining investor confidence and accelerating venture capital.

Careology And Entia Partner To ‘Enhance’ Remote Monitoring For Patients With Cancer

 

Careology and Entia are partnering to “alleviate the burden of routine patient assessments” on people with cancer. The two early-stage London-based health tech startups already provide services to UK National Health Service (NHS) patients.

More from Business

The Value Of Consumer Wearables Within The Clinic Is Currently Unknown, Says Cardiologist

 

“It’s quite likely [consumer wearable manufacturers] are changing the sensitivity and specificity based on consumer feedback, but not for medical reasons,” said Dipak Kotecha, a University of Birmingham professor of cardiology. Often, self-reported performance evidence from manufacturers is “low quality and biased.”

GE HealthCare Warns Of $500M Tariff Hit In 2025, Eyes Recovery in 2026

 
• By 

GE HealthCare anticipates most of the $0.85 EPS tariff impact will play out in the second half of 2025. Jay Saccaro, vice president and CFO, said the tariff-related burden is minimal in Q1 at about $10 million, rising to nearly $100 million in Q2 and then spiking to around $200 million each in Q3 and Q4.

Peerbridge Bets On At-Home Heart Monitoring With Rechargeable, Longer-Lasting ECG Patch

 
• By 

Peerbridge Health is preparing to submit its next-generation ECG patch, CorMDx, for US FDA clearance this quarter, with plans to launch in the second half of 2025. The rechargeable device is designed for continuous, real-time heart monitoring from the hospital to home, aiming to detect early signs of heart failure and reduce emergency room visits.